Yahoo Web Search

Search results

1. • 

     AbbVie hikes 2024 earnings guidance as Q1 beat estimates, shares up By Investing.com

     Investing.com· 3 days ago

     AbbVie hikes 2024 earnings guidance as Q1 beat estimates, shares up

2. • AbbVie raises earnings forecast on strong immunology drug growth

     Crain s Chicago Business· 3 days ago

     The growth helped offset sales declines of Humira, AbbVie’s once best-selling immunosuppressive medication that began facing biosimilar competition last year. Humira sales ...

3. • AbbVie Inc (ABBV) Q1 2024 Earnings Call Transcript Highlights: S

     Guru Focus· 3 days ago

     Adjusted Earnings Per Share: $2.31, $0.11 above guidance midpoint.Total Net Revenues: $12.3 billion, $400 million ahead of expectations.Ex-Humira Growth Platfo

4. • AbbVie: Q1 Earnings Snapshot - WTOP News

     WTOP Washington· 3 days ago

     NORTH CHICAGO, Ill. (AP) — NORTH CHICAGO, Ill. (AP) — AbbVie Inc. (ABBV) on Friday reported first-quarter earnings of $1.37 billion. On a per-share basis, the North Chicago…

5. • Gear Up for AbbVie (ABBV) Q1 Earnings: Wall Street Estimates for Key Metrics

     Zacks· 7 days ago

     Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. Numerous empirical studies consistently demonstrate a strong relationship ...

6. • AbbVie Lifts Profit Forecast After Skyrizi Sales Beat Expectations

     US News & World Report· 3 days ago

     US News is a recognized leader in college, grad school, hospital, mutual fund, and car rankings. Track elected officials, research health conditions, and find news you can use in politics, business, health, and education.

7. • AbbVie Lifts FY24 Outlook After Higher Q1 Results - Update

     RTT News· 3 days ago

     AbbVie Inc. (ABBV), while announcing higher first-quarter earnings, on Friday raised its outlook for fiscal 2024. In pre-market activity on the NYSE, AbbVie shares were gaining around 1.

8. • UPDATE 1-AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study

     Reuters via Yahoo Finance· 4 days ago

     AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective than Regeneron Pharmaceuticals and Sanofi's Dupixent ...

9. • AbbVie Reports First-Quarter 2024 Financial Results

     Leader-Telegram· 3 days ago

     Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These Results Include an Unfavorable

10. • AbbVie’s Q1 earnings beat expectations as arthritis drug boosts growth | Invezz

      Invezz· 3 days ago

      Pharmaceuticals company AbbVie (NYSE: ABBV) reported its Q1 financial results for 2024 today. Are you looking for signals & alerts from pro-traders? AbbVie